Nateglinide alone or with metformin safely improves glycaemia to target in patients up to an age of 84

Diabetes, Obesity and Metabolism

Volumn 6, Issue 5, 2004, Pages 344-352

  Weaver, Jola ^a   Robertson, D ^b,d   Atkin, S L ^c   Gordon, S ^d   Hayes, R ^d   Gilbey, S ^d   Reith, S ^d   O'Kane, P ^d   Duthie, I ^d   Blair, T ^d   Walker, J ^d   Jones, T ^e   Heller, S ^d   Vora, J ^d   Dineen, S ^d   Davies, M ^d   Gibson, M ^d   Reckless, J ^d   O'Hare, J ^d   Evans, P ^d   Barnett, A ^d   Gnudi, L ^f   Hyatt, P ^d   Steer, K ^g   Press, M ^h   Simpson, H ^d   Strang, C ^d   Kerr, D ^d   Gallen, I ^d   Earle, K ⁱ   Hurel, S ^j   more..

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b SANDWELL GENERAL HOSPITAL   (United Kingdom)

^c UNIVERSITY OF HULL   (United Kingdom)

^d Barneyles Hosptial ^*

^e Barneyles Hosptial   (United Kingdom)

^f GUY S HOSPITAL   (United Kingdom)

^g Northwick Park University Hospital   (United Kingdom)

^h Sheila Sherlock Liver Center   (United Kingdom)

ⁱ WHITTINGTON HOSPITAL   (United Kingdom)

^j MIDDLESEX HOSPITAL   (United Kingdom)

more..

Author keywords

First phase insulin secretion; Hypoglycaemia; Postprandial plasma glucose; Prospective study; Type 2 diabetes mellitus

Indexed keywords

GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; NATEGLINIDE; SULFONYLUREA;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONFUSION; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FEMALE; FEVER; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; HYPERTENSION; HYPOGLYCEMIA; HYPOTENSION; INDIGESTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; NERVOUSNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PARESTHESIA; SIDE EFFECT; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; STOMACH DISEASE; THORAX PAIN; TREATMENT OUTCOME; VIRUS INFECTION; VOMITING;

EID: 20844454086     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1462-8902.2004.00353.x     Document Type: Article

References (28)

1. Amos AF, McCarty D, Zimmet P. The rising global burden of diabetes and its complications; estimates and projections to the year 2010. Diabet Med 1997; 14 (Suppl. 5): 1-85.
2. Department of Health National Service Framework for Diabetes. Standards. London: Department of Health, 2001.
3. Gray A, Clarke P, Farmer A, Holman R. Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). BMJ 2002; 325: 860-863.
4. Anonymous (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-852.
5. Winocour PH. Effective diabetes care: a need for realistic targets. BMJ 2002; 324: 1577-1580.
6. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N Engl J Med 1992; 326: 22-29.
7. Weyer C, Bogardus C, Mott DM, Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999; 104: 787-794.
8. Ward WK, Beard JC, Halter JB, Pfeifer MA, D. Pathophysiology of insulin secretion in non-insulin dependent diabetes mellitus. Diabetes Care 1984; 7: 491-502.
9. Avignon A, Radauceanu A, Monnier L. Non fasting plasma glucose is a better marker of diabetic control than fasting plasma glucose in type 2 diabetes. Diabetes Care 1997; 20: 1822-1826.
10. The DECODE Study Group Glucose Tolerance and Mortality. Comparison of WHO and American Diabetes Association Diagnostic Criteria Diabetes Epidemiology: Collaborative analysis of diagnostic criteria in Europe. Lancet 1999; 354: 617-621.
11. Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ. Isolated post challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 1999; 42: 1050-1054.
12. Hanefeld M, Fisher S, Jullius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11 year follow up. Diabetologia 1996; 39: 1557-1583.
13. Bastyr EJ, Stuart CA, Brodows RG et al. Therapy focused on lowering postprandial glucose, not fasting glucose may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000; 23: 1236-1241.
14. UKPDS 16. Overview of 6 years therapy of type II diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
15. Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the US. Diabetes Care 2001; 24: 1936-1940.
16. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431.
17. McAulay V, Frier B. Hypoglycaemia. In: Sinclair A, Finucane P eds. Diabetes in Old Age, 2nd edn. Chichester: Wiley, 2000: 133-152.
18. Pratley RE, Foley JE, Dunning BE. Rapid acting insulinotropic agents: restoration of early insulin secretion as a physiologic approach to improve glucose control. Curr Pharmaceut Design 2001; 7: 1375-1397.
19. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349-353.
20. Keilson L, Mather S, Walter YH, Subramanian S. Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85: 1081-1086.
21. Carroll MF, Izard ABS, Riboni KBS, Burge MR, Schade DS. Control of postprandial hyperglycemia: Optimal use of short-acting insulin secretagogues. Diabetes Care 2002; 25: 2147-2152.
22. Hanefeld M, Boutler KP, Dickinson S, Guitard C. Rapid and short acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. Diabetes Care 2000; 23: 202-207.
23. Horton ES, Clinkingbeard C, Gatlin M, Foley J, Mallows S, Shen S. Nateglinide alone and in combination with metformin improves glycaemic control by reducing mealtime glucose levels in type 2 diabetes. Diabetes Care 2000; 23: 1660-1665.
24. Marre M, VanGaal L, Usadel K-H, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomised trial with type 2 diabetes patients. Diabetes Obes Metab 2002; 4: 177-186.
25. Raskin P, Klaff L, McGill J et al. Efficacy and safety of combination therapy: Repaglinide plus metformin versus nateglinide plus metformin. Diabetes Care 2003; 26: 2063-2068.
26. HU S, Wang S, Fanelli B et al. Pancreatic (alpha)-cell channel activity and membrane-binding studies with nateglinide: a comparison with sulphonylureas and repaglinide. J Pharmacol Exp Ther 2000; 293: 444-452.
27. Kalbag J, Hirshberg Y, McLeod JF, Garreffa S, Lasseter K. Comparison of mealtime glucose regulation by nateglinide and repaglinide in healthy subjects. Diabetes 1999; 48 (Suppl. 1): A106.
28. Saloranta C, Guitard C, Pecher E et al. Nateglinide improves early insulin secretion and controls postprandial glucose excursion in a prediabetic population. Diabetes Care 2002; 25: 21412146.